Literature DB >> 7930761

Relationship between cytosol TPS, TPA and cell proliferation.

M Gion1, R Mione, A Becciolini, M Balzi, M Correale, A Piffanelli, G Giovannini, G Saccani Jotti, M Fontanesi.   

Abstract

The serological tumor marker tissue polypeptide antigen (TPA) and the more recently identified tissue-specific polypeptide antigen (TPS) have been reported to be indicators of the proliferation rate of the tumor. In the present investigation we compared the cytosol level of the two markers with the proliferative activity of the tumor measured using the 3H-thymidine labelling index. The preliminary results presented here show that higher TLI is associated with lower cytosol levels of both TPA and TPS. TPA and TPS in the cytosol were significantly associated. These findings are in agreement with the previously demonstrated association between high TPA cytosol levels and better prognosis in breast cancer. Further studies are ongoing in order to: 1. confirm these findings in a larger patient series; 2. investigate any possible prognostic indication provided by TPS; 3. evaluate any possible biological meaning of the negative association between TPA/TPS and TLI in the cytosol of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930761     DOI: 10.1177/172460089400900208

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  3 in total

Review 1.  -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Int J Biol Markers       Date:  2011-09-21       Impact factor: 2.659

2.  Serum M3/M21 in ovarian cancer patients.

Authors:  C Tempfer; L Hefler; G Haeusler; G Sliutz; E Hanzal; A Reinthaller; C H Kainz
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.

Authors:  C Tempfer; L Hefler; H Heinzl; A Loesch; G Gitsch; H Rumpold; C Kainz
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.